



talquetamab solution for injection (Talvey®)

Janssen-Cilag Ltd

05 July 2024

ADVICE: in the absence of a submission from the holder of the marketing authorisation **talquetamab (Talvey®)** is not recommended for use within NHSScotland.

Indication under review: As monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and have demonstrated disease progression on the last therapy.

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

The holder of the marketing authorisation has indicated that they plan to make a submission to SMC in the future.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair

Scottish Medicines Consortium